X0306 4 2022-02-08 0 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001561458 Fridriksdottir Hafrun C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL 0 1 0 0 Executive VP, Global R&D Ordinary Shares 2022-02-09 4 M 0 16121 A 57532.514 D Ordinary Shares 2022-02-09 4 S 0 6116 9.0602 D 51416.514 D Restricted Share Units 2022-02-09 4 M 0 16121 0.00 D Ordinary Shares 16121 0 D Restricted Share Units 2022-02-08 4 A 0 51488 0.00 A Ordinary Shares 51488 51488 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on February 9, 2018, with 16,120 having vested on each of February 9, 2020 and February 9, 2021 and 16,121 having vested on February 9, 2022. Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. /s/ Dov Bergwerk as attorney-in-fact for Hafrun Fridriksdottir 2022-02-10